Literature DB >> 20068150

Insertional mutagenesis in mice deficient for p15Ink4b, p16Ink4a, p21Cip1, and p27Kip1 reveals cancer gene interactions and correlations with tumor phenotypes.

Jaap Kool1, Anthony G Uren, Carla P Martins, Daoud Sie, Jeroen de Ridder, Geoffrey Turner, Miranda van Uitert, Konstantin Matentzoglu, Wendy Lagcher, Paul Krimpenfort, Jules Gadiot, Colin Pritchard, Jack Lenz, Anders H Lund, Jos Jonkers, Jane Rogers, David J Adams, Lodewyk Wessels, Anton Berns, Maarten van Lohuizen.   

Abstract

The cyclin dependent kinase (CDK) inhibitors p15, p16, p21, and p27 are frequently deleted, silenced, or downregulated in many malignancies. Inactivation of CDK inhibitors predisposes mice to tumor development, showing that these genes function as tumor suppressors. Here, we describe high-throughput murine leukemia virus insertional mutagenesis screens in mice that are deficient for one or two CDK inhibitors. We retrieved 9,117 retroviral insertions from 476 lymphomas to define hundreds of loci that are mutated more frequently than expected by chance. Many of these loci are skewed toward a specific genetic context of predisposing germline and somatic mutations. We also found associations between these loci with gender, age of tumor onset, and lymphocyte lineage (B or T cell). Comparison of retroviral insertion sites with single nucleotide polymorphisms associated with chronic lymphocytic leukemia revealed a significant overlap between the datasets. Together, our findings highlight the importance of genetic context within large-scale mutation detection studies, and they show a novel use for insertional mutagenesis data in prioritizing disease-associated genes that emerge from genome-wide association studies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20068150      PMCID: PMC2875110          DOI: 10.1158/0008-5472.CAN-09-2736

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

Review 1.  CDK inhibitors: cell cycle regulators and beyond.

Authors:  Arnaud Besson; Steven F Dowdy; James M Roberts
Journal:  Dev Cell       Date:  2008-02       Impact factor: 12.270

2.  Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis.

Authors:  N E Sharpless; N Bardeesy; K H Lee; D Carrasco; D H Castrillon; A J Aguirre; E A Wu; J W Horner; R A DePinho
Journal:  Nature       Date:  2001-09-06       Impact factor: 49.962

Review 3.  Retroviral insertion mutagenesis in mice as a comparative oncogenomics tool to identify disease genes in human leukemia.

Authors:  Ivo P Touw; Stefan J Erkeland
Journal:  Mol Ther       Date:  2007-01       Impact factor: 11.454

4.  Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.

Authors:  Joshua Wechsler; Marianne Greene; Michael A McDevitt; John Anastasi; Judith E Karp; Michelle M Le Beau; John D Crispino
Journal:  Nat Genet       Date:  2002-08-12       Impact factor: 38.330

5.  High-throughput retroviral tagging for identification of genes involved in initiation and progression of mouse splenic marginal zone lymphomas.

Authors:  Min Sun Shin; Torgny N Fredrickson; Janet W Hartley; Takeshi Suzuki; Keiko Akagi; Keiko Agaki; Herbert C Morse
Journal:  Cancer Res       Date:  2004-07-01       Impact factor: 12.701

6.  Phosphorylated VEGFR2/KDR receptors are widely expressed in B-cell non-Hodgkin's lymphomas and correlate with hypoxia inducible factor activation.

Authors:  Alexandra Giatromanolaki; Michael I Koukourakis; Francesco Pezzella; Efthimios Sivridis; Helen Turley; Adrian L Harris; Kevin C Gatter
Journal:  Hematol Oncol       Date:  2008-12       Impact factor: 5.271

7.  Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome.

Authors:  Gina Kirsammer; Sarah Jilani; Hui Liu; Elizabeth Davis; Sandeep Gurbuxani; Michelle M Le Beau; John D Crispino
Journal:  Blood       Date:  2007-09-27       Impact factor: 22.113

8.  Co-occurrence analysis of insertional mutagenesis data reveals cooperating oncogenes.

Authors:  Jeroen de Ridder; Jaap Kool; Anthony Uren; Jan Bot; Lodewyk Wessels; Marcel Reinders
Journal:  Bioinformatics       Date:  2007-07-01       Impact factor: 6.937

9.  CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast cancer loss of heterozygosity region at 16q24.3.

Authors:  Marina Kochetkova; Olivia L D McKenzie; Anthony J Bais; Julie M Martin; Genevieve A Secker; Ram Seshadri; Jason A Powell; Susan J Hinze; Alison E Gardner; Hayley E Spendlove; Nathan J O'Callaghan; Anne-Marie Cleton-Jansen; Cees Cornelisse; Scott A Whitmore; Joanna Crawford; Gabriel Kremmidiotis; Grant R Sutherland; David F Callen
Journal:  Cancer Res       Date:  2002-08-15       Impact factor: 12.701

10.  Automated generation of heuristics for biological sequence comparison.

Authors:  Guy St C Slater; Ewan Birney
Journal:  BMC Bioinformatics       Date:  2005-02-15       Impact factor: 3.169

View more
  18 in total

1.  Cyclin dependent kinase inhibitors differentially modulate synergistic cytokine responsiveness of hematopoietic progenitor cells.

Authors:  Hal E Broxmeyer; David S Franklin; Scott Cooper; Giao Hangoc; Charlie Mantel
Journal:  Stem Cells Dev       Date:  2011-11-02       Impact factor: 3.272

2.  Mouse models of cancer as biological filters for complex genomic data.

Authors:  Elisa Oricchio; Andrew L Wolfe; Jonathan H Schatz; Konstantinos J Mavrakis; Hans-Guido Wendel
Journal:  Dis Model Mech       Date:  2010-09-27       Impact factor: 5.758

3.  Plac8 links oncogenic mutations to regulation of autophagy and is critical to pancreatic cancer progression.

Authors:  Conan Kinsey; Vijaya Balakrishnan; Michael R O'Dell; Jing Li Huang; Laurel Newman; Christa L Whitney-Miller; Aram F Hezel; Hartmut Land
Journal:  Cell Rep       Date:  2014-05-01       Impact factor: 9.423

4.  A genome-wide association study identifies genetic variants in the CDKN2BAS locus associated with endometriosis in Japanese.

Authors:  Satoko Uno; Hitoshi Zembutsu; Akira Hirasawa; Atsushi Takahashi; Michiaki Kubo; Tomoko Akahane; Daisuke Aoki; Naoyuki Kamatani; Koichi Hirata; Yusuke Nakamura
Journal:  Nat Genet       Date:  2010-07-04       Impact factor: 38.330

5.  Profibrotic role of miR-154 in pulmonary fibrosis.

Authors:  Jadranka Milosevic; Kusum Pandit; Marcus Magister; Einat Rabinovich; Daniel C Ellwanger; Guoying Yu; Louis J Vuga; Benny Weksler; Panayiotis V Benos; Kevin F Gibson; Michael McMillan; Michael Kahn; Naftali Kaminski
Journal:  Am J Respir Cell Mol Biol       Date:  2012-10-04       Impact factor: 6.914

6.  High-throughput semiquantitative analysis of insertional mutations in heterogeneous tumors.

Authors:  Marco J Koudijs; Christiaan Klijn; Louise van der Weyden; Jaap Kool; Jelle ten Hoeve; Daoud Sie; Pramudita R Prasetyanti; Eva Schut; Sjors Kas; Theodore Whipp; Edwin Cuppen; Lodewyk Wessels; David J Adams; Jos Jonkers
Journal:  Genome Res       Date:  2011-08-18       Impact factor: 9.043

7.  Deregulated Nras expression in knock-in animals harboring a gammaretroviral long terminal repeat at the Nras/Csde1 locus.

Authors:  Borja Ballarín-González; Louise Berkhoudt Lassen; Randi Jessen; Annette Füchtbauer; Ernst-Martin Füchtbauer; Finn Skou Pedersen
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

Review 8.  Insertional oncogenesis by non-acute retroviruses: implications for gene therapy.

Authors:  Hung Fan; Chassidy Johnson
Journal:  Viruses       Date:  2011-04-15       Impact factor: 5.048

9.  Insights into Assessing the Genetics of Endometriosis.

Authors:  Nilufer Rahmioglu; Stacey A Missmer; Grant W Montgomery; Krina T Zondervan
Journal:  Curr Obstet Gynecol Rep       Date:  2012-06-15

10.  Analysis of tumor heterogeneity and cancer gene networks using deep sequencing of MMTV-induced mouse mammary tumors.

Authors:  Christiaan Klijn; Marco J Koudijs; Jaap Kool; Jelle ten Hoeve; Mandy Boer; Joost de Moes; Waseem Akhtar; Martine van Miltenburg; Annabel Vendel-Zwaagstra; Marcel J T Reinders; David J Adams; Maarten van Lohuizen; John Hilkens; Lodewyk F A Wessels; Jos Jonkers
Journal:  PLoS One       Date:  2013-05-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.